Inspire Announces Inspire Research Accelerator Initiative
Inspire Founder/CEO Brian Loew has announced a new initiative, the Inspire Research Accelerator, a program that aims to accelerate medical progress by enabling academic researchers around the world—at no cost—to collaborate with Inspire.
“The Accelerator’s goal is to enable scientific discovery by connecting researchers with patients, especially those affected by rare diseases,” Loew said.
The Accelerator will aim to help propel research in a variety of ways:
- Unlocking research gaps using longitudinal instruments, especially for personalized medicine and rare diseases
- Identifying and engaging with cancer and rare disease patient populations based on specific clinical trials experience and interest
- Rapidly deploying validated Patient-Reported Outcome (PRO) measurement tools
- Furthering exploration of complex disease underpinnings by correlating structured and unstructured data and phenotypes reported by patients with other data types such as genomics/multi-omics and other biological data
Read the full release, here.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
